Gilead Sciences stock price forecast: $120.19 support in focus as GILD slides 1.82%

Traders Union
All News
Financial News
Gilead Sciences drops 1.82% today

Highlights

Gilead Sciences delivered a moderate 3.1% annualized revenue growth rate over the past five years, reflecting steady but limited expansion.
Ongoing advancement and commercialization in HIV, viral hepatitis, COVID-19, and oncology therapies support Gilead’s long-term industry presence.
Technicals signal persistent bearish momentum, with consensus downside risk and next 2–3 day range projection of $120.19–$125.63.

Modest revenue growth persists amid sector stability and weak price action

Gilead Sciences reported an annualized revenue growth rate of 3.1% over the last five years, as noted by Finance Yahoo. This steady revenue trajectory underscores the company's ongoing presence in the pharmaceutical sector but points to only modest top-line expansion in recent years. The company's continued development and commercialization of treatments for HIV, viral hepatitis, COVID-19, and cancer further contribute to its fundamental profile, though price action has remained under broader selling pressure.

Downside momentum intensifies with resistance at Kijun and oversold signals

On the technical front, GILD is trading below its MA-20 ($125.36), MA-50 ($124.81) on the H1 chart, and well under the long-term MA-200 ($129.35). The Ichimoku Kijun at $125.32 serves as immediate resistance. Momentum indicators remain negative, with MACD signaling Sell and ADX in a neutral stance. The RSI stands at 37.43, confirming oversold conditions alongside Stoch RSI, CCI, and BBP, all suggesting seller momentum. The Awesome Oscillator is also on Sell, and price action has concluded near the daily low amid elevated volatility—all confirming heightened downside momentum.

Bearish outlook dominates as consolidation range faces volatility risk

In the short term, the expected range for GILD is $120.19 to $125.63, representing a typical volatility band relative to current levels. There is a 24% probability of an upward move versus a 76% chance of further decline according to provider data. The base case is for price consolidation within this established range. A break above the $125.32 Kijun resistance could generate upside momentum, while a downward move below $120.19 would likely accelerate selling as sellers retain control.

Anton Kharitonov, expert at Traders Union, observes that Gilead Sciences faces persistent technical weakness as price remains below all major moving averages. He believes modest fundamental performance and ongoing development in key therapeutic areas are not yet sparking a reversal in sentiment or price action. The analyst sees downside momentum dominating in the short term, with sellers holding control unless key resistance levels are reclaimed. "Until GILD breaks above $125.32, I remain cautious and expect further pressure on the stock."

Previously it was reported that Gilead Sciences was facing ongoing selling pressure and lacked decisive momentum for a near-term recovery. With today’s continuation of technical weakness and heightened downside probability, traders should closely monitor for any break below $120.19, which could trigger further selling acceleration.

Source of Data: GILD Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.